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Objective: To report on the design, methodology, and early outcome results of a
multi-institutional registry study of prostate cancer radiosurgery.
Methods:The Registry for Prostate Cancer Radiosurgery (RPCR) was established in 2010 to
further evaluate the efficacy and toxicity of prostate radiosurgery (SBRT) for the treatment
of clinically localized prostate cancer. Men with prostate cancer were asked to voluntar-
ily participate in the registry. Demographic, baseline medical, and treatment-related data
were collected and stored electronically in a Health Insurance Portability and Account-
ability Act-compliant database, maintained by Advertek, Inc. Enrolled men were asked to
complete short, multiple choice questionnaires regarding their bowel, bladder, and sexual
function. Patient-reported outcome forms were collected at baseline and at regular intervals
(every 3–6 months) following treatment. Serial prostate-specific antigen measurements
were obtained at each visit and included in the collected data.
Results: From July 2010 to July 2013, nearly 2000 men from 45 participating sites were
enrolled in the registry. The majority (86%) received radiosurgery as monotherapy. At
2 years follow-up, biochemical disease-free survival was 92%. No Grade 3 late urinary toxic-
ity was reported. One patient developed Grade 3 gastrointestinal toxicity (rectal bleeding).
Erectile function was preserved in 80% of men <70 years old. Overall compliance with
data entry was 64%.
Conclusion: Stereotactic radiosurgery is an alternative option to conventional radiotherapy
for the treatment of organ-confined prostate cancer. The RPCR represents the collec-
tive experience of multiple institutions, including community-based cancer centers, with
outcome results in keeping with published, prospective trials of prostate SBRT.
Keywords: prostate radiosurgery stereotactic, prostate SBRT, observational research, hypofractionated stereotactic
radiation, CyberKnife robotic radiosurgery
BACKGROUND
The feasibility of image-guided robotic radiosurgery for treating
localized prostate cancer was first described by King at Stanford
University (1). His phase I protocol delivered 36.25 Gy in five
fractions of 7.25 Gy to the prostate using a CyberKnife treatment
platform. He initially reported on acute and 18-month late toxi-
city in 26 low-risk patients. No patient experienced grade 3 or 4
acute or late toxicity, and only one patient experienced grade 2 late
morbidity (urethral stricture). The mean prostate-specific antigen
(PSA) at 18 months after treatment was 0.22 ng/ml. This was fol-
lowed by a prospective Phase II clinical trial for 41 low-risk prostate
cancer patients with 6 months’ minimum follow-up (1). The early
(<3 months) and late (>6 months) urinary and rectal toxicities
were assessed using validated quality of life questionnaires includ-
ing the International Prostate Symptom Score (IPSS), Expanded
Prostate Cancer Index Composite score and the Radiation Ther-
apy Oncology Group (RTOG) toxicity criteria. Patterns of PSA
response were also analyzed. At a median follow-up of 33 months,
there were no RTOG Grade 4 acute or late rectal/urinary compli-
cations. There were two patients with RTOG Grade 3 late urinary
toxicity and none with RTOG Grade 3 rectal complications. At last
follow-up, no patient has had a PSA failure. Of 32 patients with
12 months minimum follow-up, 25 patients (78%) achieved a PSA
nadir 0.4 ng/ml. A PSA decline to progressively lower nadirs up to
3 years after treatment was observed.
The Multi-institutional Registry for Prostate Cancer Radio-
surgery (RPCR, Inc.), a not-for-profit, 501c-6 organization, was
established in 2010 to further evaluate the efficacy and toxicity
of stereotactic radiosurgery in the treatment of prostate can-
cer. RPCR, Inc. originated as a collaborative effort between the
Florida Robotic Radiosurgery Association (now closed) and sev-
eral community-based radiosurgery centers in Florida. The ini-
tial goal was to collect data on prostate cancer patients treated
with hypofractionated, stereotactically delivered radiation at non-
academic radiosurgery centers in Florida, and share this “real
world” experience with the Centers for Medicare and Medicaid
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Services (CMS) and the Medicare Administrative Contractor for
Florida, First Coast Service Options.
RPCR, Inc. launched the registry in July 2010, and by the end
of the first year, more than 300 patients had been enrolled. Radio-
surgery centers outside of Florida became interested in having
a data collection tool for their prostate cancer patients, and the
once Florida-based project was gradually expanded to its current
form: a multi-state, multi-institutional database specifically for
prostate cancer patients treated with hypofractionated radiation
using stereotactic techniques.
METHODS
The original platform for the RPCR registry database was mod-
eled on a pre-existing registry database managed by the former
CyberKnife Society, now the Radiosurgical Society (RSS). That
registry, now known as the RSSearch™ Registry, was designed to
collect data on SRS and SBRT treatment practices and outcomes
for all disease sites and help establish “best practice” guidelines
for SRS/SBRT delivery (2). Both the RPCR and RSSearch™ reg-
istries are housed and maintained by Advertek, Inc., a medical
software company from Louisville, KY, USA. Founded in 1999,
Advertek focuses on software and internet-based applications
for the management of research data, patient documentation,
statistical analysis, and medical web communications.
Since the RPCR registry was conceived to address the con-
cerns of CMS and First Coast Service Options regarding coverage
of prostate radiosurgery, RPCR’s development team borrowed
data fields created for the prostate sub-section of the RSSearch™
Registry and re-structured them to focus on the data elements
important to third-party payers, namely disease-specific out-
comes and quality of life measures. In addition, data fields were
streamlined to facilitate data entry by community-based oncol-
ogy practices, most of whom do not have the infrastructure to
support a dedicated research team. RPCR, Inc. contracted with
Advertek, Inc. to house and maintain the patient data. Advertek
insures that the RPCR registry database strictly complies with
all Health Insurance Portability and Accountability Act (HIPAA)
requirements for system security and privacy. Access to individ-
ual patient data is restricted to authorized, site-specific users, and
aggregate data analyses are conducted not by RPCR users but
by independent contractors with access to only selected patient
information.
The RPCR registry database is divided into three main sections,
or “forms”: screening, treatment, and follow-up. Each new patient
enrolled in the RPCR registry is assigned a unique registry identifi-
cation number by Advertek, and participating sites are responsible
for linking this number with the appropriate patient at their site.
No patient names or initials are recorded in the database. The
only persons or organizations able to see identifying informa-
tion are select staff at the patient’s local treatment facility and
the independent database vendor (Advertek). No other partici-
pant in the RPCR registry has access to these unique identification
numbers.
Information captured in the screening form includes referral
source, third-party payer, radiation delivery device, patient age,
Karnofsky performance status, rationale for radiosurgery, initial
TNM stage, Gleason score, number of positive biopsy cores, use
of hormonal therapy, and several baseline measures, including
pre-treatment PSA, IPSS, International Index of Erectile Function
(IIEF-5) score, Bowel Health Inventory score, and Visual Analog
pain score, the last of which CMS requested be added.
The treatment form selected by a participating site depends
on which technical device is used to deliver the radiosurgery, but
all capture date of initial treatment, date of treatment completion,
dose calculation method, plan type (isocentric vs. non-isocentric),
number of fractions, number of active beams, tracking method
used (fiducials vs. cone beam CT), collimator type (fixed vs.
dynamic), prescribed dose, delivered dose, total monitor units,
and maximum dose delivered. Doses to specific organs at risk,
including rectum, bladder, penile bulb, and testicles, are also
recorded.
The follow-up form repeats many of the elements of the initial
screening form, including performance status, pain score, patient-
reported outcome scores, and post-treatment PSA. It also includes
physician assessment of potential treatment-related toxicity, using
Common Toxicity Criteria for Adverse Event Reporting, version
3 (CTCAE v3). Participating sites may obtain follow-up infor-
mation as often as they choose, but RPCR encourages sites to
record follow-up data every 3 months for the first 2 years follow-
ing radiosurgical treatment and every 6–12 months thereafter, for
a minimum of 5 years.
Each treatment facility (“participating site”) in the RPCR reg-
istry is required to sign a letter of agreement with RPCR, Inc. prior
to enrolling patients in the database. Sites are informed that they
will be responsible for entering their own data into the database,
and each site is responsible for the integrity of the data entered.
RPCR, Inc. cannot validate the accuracy of data entered by any
participating site. However, quality assurance measures are built
into the system to reduce errors in electronic data entry, and staffs
at each participating site are provided with individualized training
on the web-based system by Advertek, prior to entering patient
data. While participating sites have open access to their own data,
they are restricted from access to any other site’s information.
Aggregate data analyses for benchmark comparisons are available
upon request. Any participating site may elect to exclude its own
data from aggregate reporting. In such cases, however, the par-
ticipating site may not request aggregate data, other than what is
available through published outcome reports.
Patient participation in the RPCR registry is, of course, entirely
voluntary, but patients are required to read and sign an informed
consent prior to being enrolled in the registry. The informed con-
sent advises them that they will be asked to complete short ques-
tionnaires prior to and periodically after treatment, and answer
multiple choice questions about their bowel, bladder, and sexual
functioning. They are informed that their medical information
will be protected and secure, but information related to their con-
dition and treatment may be used for aggregate data analysis.
They are specifically informed that participation in the registry
is not required for them to receive treatment for their prostate
cancer.
RESULTS
Since launching in July 2010, the RPCR registry has enrolled
over 2700 men from 45 participating sites, including academic
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centers, hospital-based practices, and free-standing centers. All
enrolled patients received stereotactic radiosurgery as at least one
component of their overall treatment for prostate cancer. The
present report will focus on the nearly 2000 patients enrolled in
the registry between July 2010 and July 2013.
Reviewing patient characteristics, the mean age of enrolled
men was 68 years (43–100). The majority (77%) were Caucasian,
with 11% African-American. Men were referred for radiosurgery
primarily by their urologists (69%), but 18% were self-referrals.
Figure 1 shows the distribution of patients according to the
NCCN recurrence risk classification for prostate cancer, based on
AJCC stage, Gleason score, and pre-treatment PSA. Mean initial,
pre-treatment PSA for all patients was 6.7 ng/ml.
Treatment forms were completed for the majority of enrolled
patients (89%). For those with recorded data, 86% were treated
using radiosurgery as monotherapy, with doses ranging from
35 to 40 Gy in four to five fractions. A small percentage (8%)
received radiosurgery as a “boost” following 45–50 Gy of external
beam radiation, with doses of 19.5–21.75 Gy in three fractions. All
patients in this report were treated on CyberKnife Robotic Radio-
surgery(R) delivery systems using fiducial tracking algorithms.
The 2-year biochemical disease-free survival (bDFS) for the
entire patient cohort was 92%. Stratified by risk group, 2-year
bDFS was 99, 97, 85, and 87% for low risk, intermediate risk
(Gleason 3+ 4), intermediate risk (Gleason 4+ 3) and high risk
patients, respectively (p= 0.03) (Figure 2). PSA levels declined
sharply in the first 6 months following radiosurgery, with a contin-
ued downward trend in PSA levels between 18 months and 2 years
following treatment (Figure 3).
Twenty-two patients experienced a rise in PSA after treatment
of more than 2 ng/ml, following a nadir level (Phoenix definition
of biochemical recurrence). However, only six of these patients
had biopsy-proven or radiographic confirmation of disease recur-
rence. Nine experienced a temporary “bounce” in PSA level that
subsequently declined, with no documented evidence of disease
recurrence. This PSA bounce phenomenon typically occurred
between 12 and 18 months following treatment, similar to the
reported experience following external beam radiation (3).
FIGURE 1 | Patient stratification according to NCCN Risk
Classifications for prostate cancer.
TOXICITY
Acute (0–3 months) and late (3–24 months) toxicity following
prostate radiosurgery was assessed using both patient-reported
outcome measures and physician evaluations. The IPSS was used
for patient-reported genitourinary symptoms. The International
FIGURE 2 | Actuarial biochemical disease-free survival, stratified by risk
group.
www.frontiersin.org January 2015 | Volume 4 | Article 369 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Freeman et al. Registry for prostate cancer radiosurgery
FIGURE 3 | Actuarial PSA response following treatment.
Index of Erectile Function (IIEF-5) was used for evaluation of
sexual function post-treatment. The Bowel Health Inventory for
men was used for patient-reported gastrointestinal symptoms.
During the first 3 months following treatment, the most com-
monly reported acute toxicities were Grade 1 urinary symptoms,
including urgency, frequency, and dysuria. IPSS scores increased
from a mean baseline of 7 to a mean score of 10 between 0
and 3 months. A similar uptick was not noted for Bowel Health
Inventory scores in the first 3 months following treatment.
Between 3 and 24 months, only one Grade 3 gastrointestinal
toxicity was reported (rectal bleeding). No Grade 3 late geni-
tourinary toxicities have been recorded. Approximately 10% of
patients reported mild urinary symptoms persisting more than
3 months following treatment. However, IPSS scores returned to
baseline levels after the initial slight increase and remained stable.
Urinary quality of life scores also remained stable post-treatment
(Figures 4–6).
Erectile function scores did show an overall downward trend
following treatment. When stratified by age, men younger than
70 years demonstrated higher baseline IIEF-5 scores (median 20 vs.
12) and maintained higher post-treatment scores (median 17 vs.
5) than men older than 70. Approximately 80% of men<70 main-
tained erections sufficient for intercourse following radiosurgery,
while only 55% of men >70 did so (Figure 7).
DISCUSSION
Several clinical studies supporting the safety and efficacy of
hypofractionated, stereotactic radiosurgery in the management
of prostate cancer have now been published. Freeman and King
reported 5-year clinical outcome results in 41 low-risk patients
from their combined institutions (4). At a median of 60 months,
the biochemical disease-free survival (DFS) was 93%. No Grade 3
rectal toxicity was noted. A single patient developed Grade 3 uri-
nary toxicity. No biochemical failures were noted after 42 months.
Katz has also published 5-year outcome results on 304 patients
with low and intermediate disease treated with CyberKnife radio-
surgery (5). Biochemical DFS was 96%; no significant toxicity was
reported.
The largest series to date is that from King et al. (6), who
reported pooled outcome results from eight institutions on 1100
patients with localized prostate adenocarcinoma, treated with
stereotactically delivered radiation. A subset of 135 patients
had a minimum of 5 years follow-up. The actuarial bDFS at
5 years was 97% for low-risk patients. For intermediate/high
risk patients, bDFS was 90%. No grade 3 toxicity was reported.
Katz recently published 6-year outcome data on 300+ low- and
intermediate-risk patients from a single institution, with simi-
lar results (7). The prescribed dose per fraction in both of these
series was>5 Gy, which is now commonly referred to as “extreme”
hypofractionation.
In 2012, the American Society of Therapeutic Radiation Oncol-
ogy (ASTRO) released a revised position statement on the use
of radiosurgery in the management of prostate cancer. “It is
ASTRO’s opinion that data supporting the use of SBRT for prostate
cancer have matured to a point where SBRT could be consid-
ered as an appropriate alternative for select patients with low to
intermediate-risk disease” (8). The National Cancer Care Net-
work guidelines, version 2.2014, now include radiosurgery as a
treatment alternative for low-intermediate-risk prostate cancer
patients. “Extremely hypofractionated image-guided IMRT/SBRT
regimens are an emerging treatment modality, with single institu-
tion and pooled reports of similar efficacy and toxicity to conven-
tionally fractionated regimens. They can be considered as a cau-
tious alternative to conventionally fractionated regimens at clinics
with appropriate technology, physics, and clinical expertise” (9).
When the RPCR registry was conceptualized in 2009, how-
ever, much of this data had not yet been published. The first
patient treated in the U.S. with “extremely hypofractionated”
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FIGURE 4 | IPSS scores at baseline and following treatment.
FIGURE 5 | Urinary quality of life following treatment.
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FIGURE 6 | Bowel Health Inventory scores at baseline and following treatment.
FIGURE 7 | Erectile function (potency) following treatment.
radiosurgery for prostate cancer was at Stanford Hospital in
2003. A few community-based centers opened single institu-
tion, prospective protocols for prostate radiosurgery shortly
thereafter, including Naples Hospital (Freeman and Friedland)
in 2005 and Winthrop Hospital (Katz) in 2006. Accuray, Inc.
launched two industry-sponsored, multi-center prospective tri-
als for CyberKnife prostate SBRT in 2008, one using homogeneous
dose distributions and the other heterogeneous dose distributions,
but patient accrual was not completed until 2012, and initial results
from these trials have only recently been published (10).
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Prior to 2009, the lack of published outcome data on prostate
radiosurgery made it understandably difficult for CMS and other
third-party payers to define coverage guidelines for this “new”
treatment modality for prostate cancer. Submitted claims to
Medicare for prostate radiosurgery were handled on a case by
case basis. Some regional Medicare Administrative Contractors
(MAC’s) developed coverage policies that proposed non-coverage
of prostate radiosurgery. In the fall of 2009, First Coast Service
Options, the MAC for Florida, released a Local Coverage Determi-
nation (LCD) for stereotactic radiosurgery and stereotactic body
radiotherapy. (An LCD is a decision by a MAC regarding whether
to cover a particular service and whether the service is reasonable
and necessary.) Prostate cancer was not included in the list of cov-
ered diagnoses for SBRT, based on the lack of long term, published
outcome data. However, “favorable consideration” would be given
to prostate cancer patients receiving SBRT who were enrolled in a
clinical trial1.
In April, 2010, the Medicare Evidence Development and Cov-
erage Advisory Committee (MEDCAC) convened in Baltimore,
MD, USA to review the clinical evidence for radiation therapy
in the management of localized prostate cancer. The committee
determined that data on the comparative effectiveness between
different forms of radiation treatments, including 3D conformal
therapy, IMRT, low dose rate and high dose rate brachytherapy,
proton therapy, and SBRT, were inconclusive as to whether one
form of radiation therapy was superior to another in terms of
overall or disease-specific survival. An apparent “evidence gap”
existed. Discussion among many panelists and presenters identi-
fied registries, particularly research-based, observational clinical
registries such as the RPCR registry, as one method of “bridging”
this evidence gap.
In simplest terms, an observational registry is a “collection of
selected information about a group of patients who share a com-
mon condition or experience” (11). As research tools, registries
have been criticized for lack of standardization in data collection,
limitations in patient participation due to educational barriers,
and the questionable reliability of self-reported data That said,
registries can provide valuable information for both clinicians and
patients. Observational registry outcome data paved the way for
MammoSite™ accelerated partial breast radiation to be accepted
in clinical radiation oncology practice. The American Society of
Breast Surgeons MammoSite Breast Brachytherapy Registry Trial
launched in 2002 in multiple centers across the United States. Six-
year outcome data on 1440 patients were published in 2012, show-
ing low local recurrence rates in the treated breast, comparable to
standard, whole-breast radiation, with good/excellent cosmesis in
90% of patients (12). Balloon brachytherapy was subsequently
included as one arm of the NSABP/RTOG B39 prospective, ran-
domized clinical trial comparing various partial breast irradiation
techniques. Due to the growing popularity of registry databases,
the Agency for Healthcare Research and Quality (AHRQ) actually
launched a “registry of patient registries” in 2012 to facilitate
patient and physician access to these various research efforts (13).
The RPCR is among the listed studies.
1Medicare Part B Local Coverage Determination (LCD) Comment Summary. (2009,
Draft comments 155452).
Has the RPCR registry been successful thus far in bridging
the evidence gap for prostate SBRT? Certainly, patient accrual
has been better than anticipated when the registry first opened
in 2010 with 10 sites in Florida. The number of participating
sites continues to grow, in large part due to “favorable consid-
eration” being given to registry participation by most Medicare
Administrative Contractors across United States. A stable technical
platform, a user-friendly database, and readily available technical
support are also significant factors in the registry’s success. The
relatively inexpensive enrollment costs ($5000 for 3-year partic-
ipation) have made the RPCR registry accessible to community-
based cancer centers as well as academic centers. Perhaps most
importantly, participating sites have a genuine interest in offering
quality cancer care to their patients, and many use the registry
as a metric to compare their outcome results with those of their
colleagues.
Like most registry studies, the RPCR registry faces several ongo-
ing challenges. Compliance with data entry, particularly follow-up
data, has been sub-optimal. While nearly 90% of enrolled patients
have complete screening and treatment information in the data-
base, only 64% have complete follow-up data. In an effort to
improve compliance, RPCR, Inc. recently partnered with Vision-
Tree™,Inc. to develop an online patient-reported outcomes system
for the RPCR registry. Using a secure, web-based environment,
patients can now complete their required outcome forms (IPSS,
IIEF-5, and Bowel Health Inventory) without having to travel to a
physician’s office.
Maintaining quality and integrity of the data is another chal-
lenge. RPCR, Inc. does not have the resources to support a Data
Safety Monitoring Board or Quality Assurance committee. How-
ever, all data analyses and compliance reports to date have been
generated by independent contractors, outside the RPCR reg-
istry system, and with restricted access to aggregate data. Any
data outlier (a result not within the expected range for a given
data field) is reported to RPCR’s compliance officer for validation
and/or correction. To maintain interest in the registry’s contin-
ued success, RPCR, Inc. will be distributing annual reports of
outcome results to all participating sites, expanding the database
to include a variety of treatment platforms, and continuing to
collaborate with colleagues from the RSS, Cyberknife Coalition,
and CMS.
CONCLUSION
Registry for Prostate Cancer Radiosurgery, Inc. started as a grass-
roots effort by a few physicians with a common goal: to bring
prostate radiosurgery to the mainstream of treatment options
for patients with prostate cancer. Four years, 45 sites, and 2700
patients later, the RPCR registry has become a robust clini-
cal database, with outcome results comparable to those from
several prospective clinical trials. The RPCR registry represents
“real world” experience, and offers non-academic, community-
based cancer centers the opportunity to contribute their patient
data to a growing body of clinical knowledge about prostate
radiosurgery. As the data continue to mature and mecha-
nisms for capturing follow-up data improve, we look forward
to sharing long-term outcome results from the RPCR registry
database.
www.frontiersin.org January 2015 | Volume 4 | Article 369 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Freeman et al. Registry for prostate cancer radiosurgery
ACKNOWLEDGMENTS
The authors would like to thank John Bandela, MD and Advertek,
Inc. for their assistance with data analysis and the creation of the
supporting figures for this manuscript.
REFERENCES
1. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic
body radiotherapy for localized prostate cancer: interim results of a prospec-
tive phase II clinical trial. Int J Radiat Oncol Biol Phys (2009) 73:1043–8.
doi:10.1016/j.ijrobp.2008.05.059
2. Davis JN, Medbery C, Sharma S, Danish A, Mahadevan A. The RSSearch reg-
istry: patterns of care and outcomes research on patients treated with stereotac-
tic radiosurgery and stereotactic body radiotherapy. Radiat Oncol (2013) 8:275.
doi:10.1186/1748-717X-8-275
3. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, et al. Prostate
specific antigen bounce phenomenon after external beam radiation for clini-
cally localized prostate cancer. J Urol (2002) 168(5):2001–5. doi:10.1016/S0022-
5347(05)64282-6
4. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate can-
cer: five year outcomes. Radiat Oncol (2011) 6:3. doi:10.1186/1748-717X-6-3
5. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiother-
apy for organ-confined prostate cancer. BMC Urol (2010) 10:1. doi:10.1186/
1471-2490-10-1
6. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic
body radiotherapy for localized prostate cancer: pooled analysis from a multi-
institutional consortium of prospective phase II trials. Radiother Oncol (2013)
109(2):217–21.
7. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for
localized prostate cancer: disease control and quality of life at 6 years. Radiat
Oncol (2013) 8:118. doi:10.1186/1748-717X-8-118
8. American Society for Therapeutic Radiation Oncology. Model Pol-
icy: Stereotactic Body Radiation Therapy (SBRT). (2013). Available
from: https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/
Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf
9. NCCN Clinical Practice Guidelines in Oncology(tm) (NCCN). Prostate Can-
cer (V.2.2014). National Comprehensive Cancer Network, Inc. (2013). Available
from: http://www.nccn.org/index.asp
10. Meier R. Stereotactic body radiation therapy for intermediate-risk organ-
confined prostate cancer: interim toxicity and quality of life outcomes from a
multi-institutional study. Int J Radiat Oncol Biol Phys (2012) 84(3 Suppl):S148.
doi:10.1016/j.ijrobp.2012.07.382
11. Gliklich RE, Dreyer NA. Registries for Evaluating Patient Outcomes: A User’s
Guide (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Out-
come]Under Contract No.HHSA29020050035ITO1. Rockville, MD: AHRQ Pub-
lication (2010).
12. Khan AJ, Arthur D, Vicini F, Beitsch P, Kuerer H, Goyal S, et al. Six-year
analysis of treatment-related toxicities in patients treated with accelerated
partial breast irradiation on the American society of breast surgeons Mam-
moSite breast brachytherapy registry trial. Ann Surg Oncol (2012) 19:1477–83.
doi:10.1245/s10434-011-2133-1
13. Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, et al. Stereo-
tactic Body Radiation Therapy [Internet]. Rockville, MD: Agency for Healthcare
Research and Quality (US) (2011). Available from: http://www.ncbi.nlm.nih.
gov/books/NBK55723/
Conflict of Interest Statement: Debra Freeman, MD was previously employed by
Accuray, Inc. in the Dept. of Medical Affairs from August 2008 to January 2010 and
served as a medical consultant until January 2012. Drs. Dickerson and Perman have
no competing interests.
Received: 29 September 2014; accepted: 04December 2014; published online: 22 January
2015.
Citation: Freeman D, Dickerson G and Perman M (2015) Multi-institutional registry
for prostate cancer radiosurgery: a prospective observational clinical trial. Front. Oncol.
4:369. doi: 10.3389/fonc.2014.00369
This article was submitted to Radiation Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2015 Freeman, Dickerson and Perman. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Oncology | Radiation Oncology January 2015 | Volume 4 | Article 369 | 8
